Patents by Inventor Dimitri E Grigoriadis

Dimitri E Grigoriadis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
    Publication number: 20240058342
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Application
    Filed: July 14, 2023
    Publication date: February 22, 2024
    Inventor: Dimitri E. Grigoriadis
  • Treatment of congenital adrenal hyperplasia
    Patent number: 11730739
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: August 22, 2023
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Dimitri E. Grigoriadis
  • Treatment of congenital adrenal hyperplasia
    Patent number: 11311544
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: April 26, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Dimitri E. Grigoriadis
  • TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
    Publication number: 20210361659
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventor: Dimitri E. Grigoriadis
  • TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
    Publication number: 20210137926
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Application
    Filed: October 20, 2020
    Publication date: May 13, 2021
    Inventor: Dimitri E. Grigoriadis
  • Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
    Publication number: 20210113553
    Abstract: Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (,S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
    Type: Application
    Filed: June 3, 2020
    Publication date: April 22, 2021
    Inventors: Christopher F. O`Brien, Dimitri E. Grigoriadis
  • Treatment of congenital adrenal hyperplasia
    Patent number: 10905690
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 2, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Dimitri E. Grigoriadis
  • Pharmaceutical Compositions Comprising an Antipsychotic Drug and a VMAT2 Inhibitor and Uses Thereof
    Publication number: 20200206215
    Abstract: New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Samuel Roger Jesse Hoare, Dimitri E. Grigoriadis, Neil J. Ashweek
  • Pharmaceutical Compositions Comprising an Antipsychotic Drug and a VMAT2 Inhibitor and Uses Thereof
    Publication number: 20190381029
    Abstract: New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.
    Type: Application
    Filed: January 16, 2019
    Publication date: December 19, 2019
    Inventors: Samuel Roger Jesse Hoare, Dimitri E. Grigoriadis, Neil J. Ashweek
  • TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
    Publication number: 20190231781
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Application
    Filed: December 20, 2018
    Publication date: August 1, 2019
    Inventor: Dimitri E. Grigoriadis
  • CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
    Publication number: 20170020877
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Application
    Filed: January 21, 2015
    Publication date: January 26, 2017
    Inventor: Dimitri E. Grigoriadis
  • Corticotropin-releasing factor receptors
    Patent number: 7034118
    Abstract: The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 25, 2006
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Timothy W Lovenberg, Tilman Oltersdorf, Chen Wang Liaw, Dimitri E Grigoriadis, Derek T Chalmers, Errol B DeSouza
  • Corticotropin-releasing factor2 receptors
    Publication number: 20040185533
    Abstract: The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
    Type: Application
    Filed: April 9, 2004
    Publication date: September 23, 2004
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Timothy W. Lovenberg, Tilman Oltersdorf, Chen Wang Liaw, Dimitri E. Grigoriadis, Derek T. Chalmers, Errol B. DeSouza
  • Corticotropin-releasing factor2 receptors
    Patent number: 6723841
    Abstract: The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: April 20, 2004
    Assignee: Neurocrine Biosciences Inc.
    Inventors: Timothy W. Lovenberg, Tilman Oltersdorf, Chen Wang Liaw, Dimitri E. Grigoriadis, Derek T. Chalmers, Errol B. DeSouza
  • Corticotropin-releasing factor2 receptors
    Publication number: 20020077468
    Abstract: The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
    Type: Application
    Filed: June 13, 2001
    Publication date: June 20, 2002
    Inventors: Timothy W. Lovenberg, Tilman Oltersdorf, Chen Wang Liaw, Dimitri E. Grigoriadis, Derek T. Chalmers, Errol B. DeSouza
  • Isolated nucleic acid encoding corticotropin-releasing factor.sub.2 receptors
    Patent number: 5786203
    Abstract: The present invention provides isolated nucleic acid molecules encoding CRF.sub.2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: July 28, 1998
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Timothy W. Lovenberg, Tilman Oltersdorf, Chen Wang Liaw, Dimitri E. Grigoriadis, Errol DeSouza